Geeta Yadav
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Geeta Yadav has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Aditya Kumar Gupta
Division of Dermatology, Department of Medicine, Temerty Faculty of Medicine, University of Toronto , Toronto, Ontario
3 shared publications - Charles W. Lynde
University of Toronto, Markham, Canada
3 shared publications Daniel Wong
DeRMA Skin Institute, Burlington, ON, Canada
3 shared publicationsDimitrios Kyritsis
Clinique de Dermatologie Protoderma, Pierrefonds Medical Center, Montreal, QC, Canada
3 shared publicationsElias Raad
L’Oréal Canada, Montreal, QC, Canada
3 shared publicationsIan Landells
Landells Clinic, Nexus Clinical Research, St. John’s, NL, Canada
3 shared publications
Latest Publications
- Open Access
- 10 September 2026
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Racial and Ethnic Differences in Psychiatric Outcomes Among Atopic Dermatitis Patients: An NIH All of Us Database Analysis
- 10 September 2026
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Open AccessRacial and Ethnic Differences in Psychiatric Outcomes Among Atopic Dermatitis Patients: An NIH All of Us Database Analysis
- Open Access
- 18 March 2026
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 30 (5) , 486-497
A Review of Post-Inflammatory Pigmentation Changes: Pathophysiology, Diagnosis and Treatment
Post-inflammatory hyperpigmentation (PIH) and hypopigmentation are heterogenous conditions that often occur secondary to dermatoses (eg, psoriasis, acne, or atopic dermatitis), cutaneous injury (eg, burns or radiation therapy), infection (viral, bacterial, or fungal), or allergic/immunologic dysregulation (eg, contact dermatitis or insect bite reactions). The pathophysiology of PIH is complex with multiple pathways implicated in hypermelanosis including ultraviolet radiation exposure, local skin inflammation, and cytokine and growth factor signalling between keratinocytes, melanocytes, and dermal fibroblasts. PIH is a clinical diagnosis based on patient history and clinical examination and may persist for months to years following the resolution of underlying pathophysiological mechanisms, emphasizing the need for prompt diagnosis and management. PIH can be disfiguring and associated with substantial impairments in quality of life and psychosocial well-being. Patients with skin of colour (ie, Fitzpatrick skin types III-VI) have an increased risk of PIH and often present with more pronounced dyspigmentation, highlighting a high unmet need for improved recognition, awareness, and management in this population. Photoprotection is the cornerstone of PIH management given the photosensitive nature of the condition and is recommended in tandem with other treatment options including topical agents (eg, hydroquinone, retinoids, tranexamic acid), light/laser-based therapies, or chemical peels (glycolic acid and salicylic acid). Despite their use, high-level clinical evidence for these treatment options in PIH remains limited. This review provides an up-to-date overview of PIH pathophysiology, diagnosis and differential diagnosis, and management, and offers expert clinical commentary on practical strategies for identifying, preventing, and managing PIH in routine practice.
- 18 March 2026
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 30 (5) , 486-497
Open AccessA Review of Post-Inflammatory Pigmentation Changes: Pathophysiology, Diagnosis and Treatment
Post-inflammatory hyperpigmentation (PIH) and hypopigmentation are heterogenous conditions that often occur secondary to dermatoses (eg, psoriasis, acne, or atopic dermatitis), cutaneous injury (eg, burns or radiation therapy), infection (viral, bacterial, or fungal), or allergic/immunologic dysregulation (eg, contact dermatitis or insect bite reactions). The pathophysiology of PIH is complex with multiple pathways implicated in hypermelanosis including ultraviolet radiation exposure, local skin inflammation, and cytokine and growth factor signalling between keratinocytes, melanocytes, and dermal fibroblasts. PIH is a clinical diagnosis based on patient history and clinical examination and may persist for months to years following the resolution of underlying pathophysiological mechanisms, emphasizing the need for prompt diagnosis and management. PIH can be disfiguring and associated with substantial impairments in quality of life and psychosocial well-being. Patients with skin of colour (ie, Fitzpatrick skin types III-VI) have an increased risk of PIH and often present with more pronounced dyspigmentation, highlighting a high unmet need for improved recognition, awareness, and management in this population. Photoprotection is the cornerstone of PIH management given the photosensitive nature of the condition and is recommended in tandem with other treatment options including topical agents (eg, hydroquinone, retinoids, tranexamic acid), light/laser-based therapies, or chemical peels (glycolic acid and salicylic acid). Despite their use, high-level clinical evidence for these treatment options in PIH remains limited. This review provides an up-to-date overview of PIH pathophysiology, diagnosis and differential diagnosis, and management, and offers expert clinical commentary on practical strategies for identifying, preventing, and managing PIH in routine practice.
- Open Access
- 2 March 2026
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (4) , 2031-2045
The Impact of Post-inflammatory Pigment Alteration After Psoriasis: Novel Data from the VISIBLE Study
Introduction Post-inflammatory pigment alteration (PIPA) in skin previously affected by psoriasis is an important, often neglected problem. PIPA has a disproportionate negative impact in people with skin of color. The phase 3b VISIBLE study evaluated guselkumab efficacy and safety in participants with skin of color and moderate-to-severe plaque psoriasis (cohort A) or moderate-to-severe scalp psoriasis (cohort B). Here we report results from exploratory assessments of the quality-of-life impact of pigmentation changes as psoriasis lesions resolve and long-term skin clearance is achieved and of correlations between dyspigmentation and clinical and patient-reported outcomes. Methods Randomized (3:1) participants received guselkumab 100 mg or placebo with crossover to guselkumab at week 16. Patient-reported impact of dyspigmentation on quality of life was assessed via Skin Discoloration Impact Evaluation Questionnaire (SDIEQ). Correlations between SDIEQ, Psoriasis Area and Severity Index (PASI), and Dermatology Life Quality Index (DLQI) were assessed. Pigmentation journeys were tracked using standard and cross-polarized photographs evaluated for erythema, pigmentation, and skin tone evenness. Results Across treatment and Fitzpatrick skin type groups (N = 205), mean SDIEQ scores decreased from 8.4–9.5 (moderate impact) at baseline to 1.3–1.9 (mild impact) at week 48. Photographic improvements in pigmentation were also observed. The majority of guselkumab-treated participants achieved clear or almost clear skin at week 48. In cohort A, mean percent PASI improvement from baseline was 94.9%; in cohort B mean percent Psoriasis Scalp Severity Index improvement was 94.6%. At week 48, correlation between SDIEQ and DLQI (r = 0.7456; p < 0.001) was stronger than between PASI and DLQI (r = 0.3345; p < 0.001). Conclusion Following treatment with guselkumab, most participants achieved clear or almost clear skin and substantial improvements in skin discoloration. Exploratory analyses showed SDIEQ improvements impacted quality of life more than PASI improvements, suggesting greater attention to PIPA is warranted in comprehensive psoriasis management, especially for patients with skin of color. ClinicalTrials.gov Identifier NCT05272150.
- 2 March 2026
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (4) , 2031-2045
Open AccessThe Impact of Post-inflammatory Pigment Alteration After Psoriasis: Novel Data from the VISIBLE Study
Introduction Post-inflammatory pigment alteration (PIPA) in skin previously affected by psoriasis is an important, often neglected problem. PIPA has a disproportionate negative impact in people with skin of color. The phase 3b VISIBLE study evaluated guselkumab efficacy and safety in participants with skin of color and moderate-to-severe plaque psoriasis (cohort A) or moderate-to-severe scalp psoriasis (cohort B). Here we report results from exploratory assessments of the quality-of-life impact of pigmentation changes as psoriasis lesions resolve and long-term skin clearance is achieved and of correlations between dyspigmentation and clinical and patient-reported outcomes. Methods Randomized (3:1) participants received guselkumab 100 mg or placebo with crossover to guselkumab at week 16. Patient-reported impact of dyspigmentation on quality of life was assessed via Skin Discoloration Impact Evaluation Questionnaire (SDIEQ). Correlations between SDIEQ, Psoriasis Area and Severity Index (PASI), and Dermatology Life Quality Index (DLQI) were assessed. Pigmentation journeys were tracked using standard and cross-polarized photographs evaluated for erythema, pigmentation, and skin tone evenness. Results Across treatment and Fitzpatrick skin type groups (N = 205), mean SDIEQ scores decreased from 8.4–9.5 (moderate impact) at baseline to 1.3–1.9 (mild impact) at week 48. Photographic improvements in pigmentation were also observed. The majority of guselkumab-treated participants achieved clear or almost clear skin at week 48. In cohort A, mean percent PASI improvement from baseline was 94.9%; in cohort B mean percent Psoriasis Scalp Severity Index improvement was 94.6%. At week 48, correlation between SDIEQ and DLQI (r = 0.7456; p < 0.001) was stronger than between PASI and DLQI (r = 0.3345; p < 0.001). Conclusion Following treatment with guselkumab, most participants achieved clear or almost clear skin and substantial improvements in skin discoloration. Exploratory analyses showed SDIEQ improvements impacted quality of life more than PASI improvements, suggesting greater attention to PIPA is warranted in comprehensive psoriasis management, especially for patients with skin of color. ClinicalTrials.gov Identifier NCT05272150.
- Open Access
- 14 January 2026
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 14
Dual biologic therapy in a patient with severe psoriasis and psoriatic arthritis, using guselkumab and bimekizumab: A case report and review of the literature
Dual biologic therapy is not often used in psoriasis and psoriatic arthritis due to cost and safety concerns, with limited literature supporting its use. We present a case of a 31-year-old man with severe plaque psoriasis and erosive psoriatic arthritis, refractory to multiple therapies. While guselkumab improved skin symptoms, joint inflammation persisted. Given the patient’s reluctance to discontinue guselkumab and his poor response to prior therapies, bimekizumab was added. This combination led to near-complete skin clearance and significant joint improvement within 3 months, with sustained benefits and no adverse effects at 17 months. This case illustrates how targeting multiple points in the interleukin-23/interleukin-17 pathway can improve outcomes in patients unresponsive to monotherapy. Dual biologic therapy may be a viable option for select patients with complex disease, though further research is needed to evaluate its long-term safety and efficacy.
- 14 January 2026
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 14
Open AccessDual biologic therapy in a patient with severe psoriasis and psoriatic arthritis, using guselkumab and bimekizumab: A case report and review of the literature
Dual biologic therapy is not often used in psoriasis and psoriatic arthritis due to cost and safety concerns, with limited literature supporting its use. We present a case of a 31-year-old man with severe plaque psoriasis and erosive psoriatic arthritis, refractory to multiple therapies. While guselkumab improved skin symptoms, joint inflammation persisted. Given the patient’s reluctance to discontinue guselkumab and his poor response to prior therapies, bimekizumab was added. This combination led to near-complete skin clearance and significant joint improvement within 3 months, with sustained benefits and no adverse effects at 17 months. This case illustrates how targeting multiple points in the interleukin-23/interleukin-17 pathway can improve outcomes in patients unresponsive to monotherapy. Dual biologic therapy may be a viable option for select patients with complex disease, though further research is needed to evaluate its long-term safety and efficacy.
- 24 October 2025
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 29 (5_suppl)
Understanding the Scalp: Dandruff and Seborrheic Dermatitis
Dandruff (DF) and seborrheic dermatitis (SD) are prevalent, chronic scalp disorders that affect a large portion of the global population, often leading to significant psychological distress and quality-of-life impairment. While DF is a milder form characterized by mild scaling, itching, and no visible inflammation, SD presents as a more severe condition with red, scaly, and often inflamed lesions. Despite the high prevalence of these conditions, research specific to their epidemiology and management in Canada remains limited. This review examines the etiology, epidemiology, and management of DF and SD from a Canadian perspective. It highlights the role of Malassezia species in the pathogenesis of both conditions and explores the influence of genetic, environmental, and microbial factors. The review also outlines the diverse clinical presentations of DF and SD across different ethnicities and the effectiveness of various over-the-counter and prescription treatments available. Additionally, the article emphasizes the lack of a Canadian consensus on the management of these conditions, calling for further research and formalized guidelines to better inform health care providers and improve patient care. Given the diverse Canadian population and the increasing burden of DF and SD, a more tailored approach to treatment is essential to address the challenges posed by these chronic conditions.
- 24 October 2025
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 29 (5_suppl)
Understanding the Scalp: Dandruff and Seborrheic Dermatitis
Dandruff (DF) and seborrheic dermatitis (SD) are prevalent, chronic scalp disorders that affect a large portion of the global population, often leading to significant psychological distress and quality-of-life impairment. While DF is a milder form characterized by mild scaling, itching, and no visible inflammation, SD presents as a more severe condition with red, scaly, and often inflamed lesions. Despite the high prevalence of these conditions, research specific to their epidemiology and management in Canada remains limited. This review examines the etiology, epidemiology, and management of DF and SD from a Canadian perspective. It highlights the role of Malassezia species in the pathogenesis of both conditions and explores the influence of genetic, environmental, and microbial factors. The review also outlines the diverse clinical presentations of DF and SD across different ethnicities and the effectiveness of various over-the-counter and prescription treatments available. Additionally, the article emphasizes the lack of a Canadian consensus on the management of these conditions, calling for further research and formalized guidelines to better inform health care providers and improve patient care. Given the diverse Canadian population and the increasing burden of DF and SD, a more tailored approach to treatment is essential to address the challenges posed by these chronic conditions.
- 23 September 2025
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 29 (5_suppl)
A Canadian Consensus on Androgenetic Alopecia: Approach and Management
Androgenetic alopecia (AGA) is the most common hair loss condition affecting between 40% to 50% of Canadian men and women by 50 years of age. This nonscarring hereditary condition can significantly affect patients, impacting their overall well-being and quality of life. Despite the multitude of interventions and the willingness of people with AGA to try treatments, there are no clear Canadian guidelines on its management. An expert panel of 11 physicians developed Delphi-based consensus recommendations of interventions for the management of AGA in male and female adults. Forty-five interventions were reviewed. Seven interventions are recommended, including oral dutasteride; oral finasteride; topical finasteride; topical minoxidil; platelet-rich plasma; microneedling; and oral minoxidil. Five interventions are recommended with near consensus: intralesional dutasteride; ketoconazole shampoo; low level laser therapy; aminexil; as part of a regimen and 17 are not recommended (adenosine; cetirizine; carboxytherapy; amla syrup; microfilament thread; Nourkrin; injectable minoxidil; caffeine; ceramide; topical herbal formulations; piroctone olamine shampoo or leave-on; rosemary oil; shampoo and lotion hair care products containing fermented papaya, fermented mangosteen, and caffeine; basic Fibroblast Growth Factor (bFGF); flutamide).
- 23 September 2025
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 29 (5_suppl)
A Canadian Consensus on Androgenetic Alopecia: Approach and Management
Androgenetic alopecia (AGA) is the most common hair loss condition affecting between 40% to 50% of Canadian men and women by 50 years of age. This nonscarring hereditary condition can significantly affect patients, impacting their overall well-being and quality of life. Despite the multitude of interventions and the willingness of people with AGA to try treatments, there are no clear Canadian guidelines on its management. An expert panel of 11 physicians developed Delphi-based consensus recommendations of interventions for the management of AGA in male and female adults. Forty-five interventions were reviewed. Seven interventions are recommended, including oral dutasteride; oral finasteride; topical finasteride; topical minoxidil; platelet-rich plasma; microneedling; and oral minoxidil. Five interventions are recommended with near consensus: intralesional dutasteride; ketoconazole shampoo; low level laser therapy; aminexil; as part of a regimen and 17 are not recommended (adenosine; cetirizine; carboxytherapy; amla syrup; microfilament thread; Nourkrin; injectable minoxidil; caffeine; ceramide; topical herbal formulations; piroctone olamine shampoo or leave-on; rosemary oil; shampoo and lotion hair care products containing fermented papaya, fermented mangosteen, and caffeine; basic Fibroblast Growth Factor (bFGF); flutamide).
- 18 September 2025
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Current Understanding of Seborrheic Dermatitis: Treatment Options
Seborrheic dermatitis is a common chronic inflammatory skin condition that primarily affects areas with a high density of sebaceous glands, such as the scalp, face, central anterior trunk, and body folds. While the exact pathophysiology of seborrheic dermatitis is not fully understood, it is believed to involve a combination of microbial dysbiosis, immune imbalance, and skin barrier dysfunction. Effective management of seborrheic dermatitis includes treatments that reduce Malassezia yeast colonization, control inflammation, normalize skin barrier dysfunction, and regulate sebum production. Topical therapies, including antifungals and anti-inflammatory agents such as corticosteroids and calcineurin inhibitors, are the mainstay of treatment of mild-to-moderate seborrheic dermatitis. Systemic therapies are reserved for severe or resistant seborrheic dermatitis cases. The recent development of new treatments, such as the topical phosphodiesterase-4 inhibitor (roflumilast 0.3% foam), shows promise in providing effective, noncorticosteroid options for seborrheic dermatitis management. This review provides an overview of current, as well as emerging therapeutic options, and discusses the importance of personalized treatment strategies in managing seborrheic dermatitis. This is the third in a series of 3 reviews, each addressing different aspects of seborrheic dermatitis, including its epidemiology, diagnosis, and treatment considerations.
- 18 September 2025
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Current Understanding of Seborrheic Dermatitis: Treatment Options
Seborrheic dermatitis is a common chronic inflammatory skin condition that primarily affects areas with a high density of sebaceous glands, such as the scalp, face, central anterior trunk, and body folds. While the exact pathophysiology of seborrheic dermatitis is not fully understood, it is believed to involve a combination of microbial dysbiosis, immune imbalance, and skin barrier dysfunction. Effective management of seborrheic dermatitis includes treatments that reduce Malassezia yeast colonization, control inflammation, normalize skin barrier dysfunction, and regulate sebum production. Topical therapies, including antifungals and anti-inflammatory agents such as corticosteroids and calcineurin inhibitors, are the mainstay of treatment of mild-to-moderate seborrheic dermatitis. Systemic therapies are reserved for severe or resistant seborrheic dermatitis cases. The recent development of new treatments, such as the topical phosphodiesterase-4 inhibitor (roflumilast 0.3% foam), shows promise in providing effective, noncorticosteroid options for seborrheic dermatitis management. This review provides an overview of current, as well as emerging therapeutic options, and discusses the importance of personalized treatment strategies in managing seborrheic dermatitis. This is the third in a series of 3 reviews, each addressing different aspects of seborrheic dermatitis, including its epidemiology, diagnosis, and treatment considerations.
- 18 September 2025
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Current Understanding of Seborrheic Dermatitis: Presentation, Diagnosis, and Special Populations
Seborrheic dermatitis is a chronic inflammatory skin condition characterized by erythematous patches and plaques with white-to-yellow greasy scale often localized to the scalp and face. Its presentation varies between children and adults, as well as across different skin tones. Notably, in patients with more richly pigmented skin, postinflammatory pigment alteration can also be a feature of seborrheic dermatitis, highlighting the importance of considering skin colour differences in the diagnosis. Clinical manifestations of seborrheic dermatitis can overlap with several other dermatoses, including atopic dermatitis, psoriasis, and rosacea, thereby necessitating careful evaluation for accurate diagnosis. The pathophysiology of seborrheic dermatitis involves a complex interplay between dermatological, neurological, immunological, and microbiome-related factors. The multifaceted nature of seborrheic dermatitis underscores the need for a comprehensive approach to its diagnosis, considering age, skin colour, cultural practices, and comorbidities. This is the second in a series of 3 reviews, each addressing different aspects of seborrheic dermatitis, including its epidemiology, diagnosis, and treatment considerations.
- 18 September 2025
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Current Understanding of Seborrheic Dermatitis: Presentation, Diagnosis, and Special Populations
Seborrheic dermatitis is a chronic inflammatory skin condition characterized by erythematous patches and plaques with white-to-yellow greasy scale often localized to the scalp and face. Its presentation varies between children and adults, as well as across different skin tones. Notably, in patients with more richly pigmented skin, postinflammatory pigment alteration can also be a feature of seborrheic dermatitis, highlighting the importance of considering skin colour differences in the diagnosis. Clinical manifestations of seborrheic dermatitis can overlap with several other dermatoses, including atopic dermatitis, psoriasis, and rosacea, thereby necessitating careful evaluation for accurate diagnosis. The pathophysiology of seborrheic dermatitis involves a complex interplay between dermatological, neurological, immunological, and microbiome-related factors. The multifaceted nature of seborrheic dermatitis underscores the need for a comprehensive approach to its diagnosis, considering age, skin colour, cultural practices, and comorbidities. This is the second in a series of 3 reviews, each addressing different aspects of seborrheic dermatitis, including its epidemiology, diagnosis, and treatment considerations.
- 18 September 2025
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Current Understanding of Seborrheic Dermatitis: Epidemiology, Burden of Disease, and Pathophysiology
Seborrheic dermatitis is a common chronic dermatosis predominantly affecting sebum-rich areas. The diagnosis of seborrheic dermatitis can be challenging due to its clinical resemblance to other dermatoses. Seborrheic dermatitis can significantly impact quality of life, particularly in those with pruritus and dyspigmentation involving the facial region. The pathogenesis of seborrheic dermatitis is complex, and while its etiology is not yet fully understood, current evidence points to a complex interplay between 3 key factors: skin microbiome dysbiosis involving Malassezia spp. overgrowth and alterations in bacterial composition, dysregulated inflammatory responses in the skin, and skin barrier dysfunction. This review provides an updated overview of seborrheic dermatitis epidemiology, burden of disease, and pathophysiology, highlighting the integral roles of microbiome, inflammation, and skin barrier dysfunction in its pathogenesis. This is the first in a series of 3 reviews, each addressing different aspects of seborrheic dermatitis, including its epidemiology, diagnosis, and treatment considerations.
- 18 September 2025
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Current Understanding of Seborrheic Dermatitis: Epidemiology, Burden of Disease, and Pathophysiology
Seborrheic dermatitis is a common chronic dermatosis predominantly affecting sebum-rich areas. The diagnosis of seborrheic dermatitis can be challenging due to its clinical resemblance to other dermatoses. Seborrheic dermatitis can significantly impact quality of life, particularly in those with pruritus and dyspigmentation involving the facial region. The pathogenesis of seborrheic dermatitis is complex, and while its etiology is not yet fully understood, current evidence points to a complex interplay between 3 key factors: skin microbiome dysbiosis involving Malassezia spp. overgrowth and alterations in bacterial composition, dysregulated inflammatory responses in the skin, and skin barrier dysfunction. This review provides an updated overview of seborrheic dermatitis epidemiology, burden of disease, and pathophysiology, highlighting the integral roles of microbiome, inflammation, and skin barrier dysfunction in its pathogenesis. This is the first in a series of 3 reviews, each addressing different aspects of seborrheic dermatitis, including its epidemiology, diagnosis, and treatment considerations.